Announcements Trials

Browse Landscape

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Ovarian Neoplasms 1 Margins of Excision 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 47 Cyclophosphamide 26 fludarabine 13 ibrutinib 12 Doxorubicin 11 Vincristine 10 Etoposide 10 Cytarabine 10 Prednisone 9 Bortezomib 9 pembrolizumab 7 fludarabine phosphate 6 Lenalidomide 6 Inotuzumab Ozogamicin 6 obinutuzumab 5 Mycophenolic Acid 5 Melphalan 5 Carmustine 5 tositumomab I-131 4 ibritumomab tiuxetan 4 Tacrolimus 4 Prednisolone 4 Methotrexate 4 Gemcitabine 4 Bendamustine Hydrochloride 4 Antilymphocyte Serum 4 tocilizumab 3 tazemetostat 3 Whole-Body Irradiation 3 Vorinostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, B-Cell × varlilumab × Clear all

NCT03307746 2024-12-02

RiVa

University Hospital Southampton NHS Foundation Trust

Phase 1/2 Completed

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡